NC
ABBV icon

Napatree Capital’s AbbVie ABBV Stock Holding History

Napatree Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$505K Buy
2,412
+294
+14% +$57.2K 0.28% 96
2024
Q4 		$376K Buy
2,118
+102
+5% +$18.8K 0.22% 119
2024
Q3 		$398K Buy
2,016
+689
+52% +$129K 0.28% 101
2024
Q2 		$228K Sell
1,327
-141
-10% -$23.4K 0.18% 128
2024
Q1 		$239K Buy
+1,468
New +$253K 0.23% 107

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Napatree Capital's ABBV Position: Q1 2025 in Review

Napatree Capital increased its AbbVie (ABBV) stake by 14% in Q1 2025, buying an estimated $57.2K and bringing the position to 2,412 shares worth $505K. The position accounts for 0.28% of the portfolio, ranked #96.

Napatree Capital first reported a position in ABBV in Q1 2024 and has held it in 5 quarters since. 3,820 funds tracked by Wall St. Rank hold ABBV as of Q1 2025.

  • Napatree Capital held 2,412 shares of AbbVie worth $505K as of Q1 2025.
  • Napatree Capital bought 294 AbbVie shares in Q1 2025, an estimated $57.2K.
  • AbbVie made up 0.28% of Napatree Capital's portfolio in Q1 2025, its #96 holding.
  • Napatree Capital first reported a position in AbbVie in Q1 2024 and has held it in 5 quarters since.
  • 3,820 funds tracked by Wall St. Rank held AbbVie as of Q1 2025.

Based on Napatree Capital's 13F filing for Q1 2025, filed 2 May 2025.